Cardiovascular Research Study for Potential Heart Attack and Stroke Prevention Drug Now Available in Santa Clarita and Warwick

BOSTON — (BUSINESS WIRE) - A research study is now available in Santa Clarita, Calif., to evaluate the effect of an investigational treatment focused on preventing heart attack and stroke in adults with high risk, but no prior history, of major adverse cardiovascular events.

Major atherosclerotic cardiovascular disease (ASCVD) events, such as heart attack and ischemic stroke, are among the leading causes of death in the United States and worldwide. The VICTORION-1 PREVENT phase 3 study by Novartis (randomized, double-blind, placebo-controlled), may offer a way to help prevent life-threatening medical emergencies caused by the buildup of plaque in the arteries.

“Heart attack and stroke impact people from all walks of life within our community and finding ways to prevent these conditions will help us live longer, healthier lives,” said Dr. Sina Tebi, Principal Investigator for Care Access - Santa Clarita. “The clinical trial will enroll patients who are at increased risk, but have no prior history, of major ASCVD events. And participants will be able to stay local, rather than travel into the city.”

The research study will enroll for adults 40 to 79 years of age who are at high risk for a first major ASCVD event, based on evidence of plaque in the coronary arteries and other factors that physicians can check for. If you or someone you know is interested or wants to participate in this study, visit managemyheartdisease.com, or contact Care Access at (351) 222-5112 to learn more.

Care Access opened its Santa Clarita location in collaboration with Dr. Tebi and other local healthcare providers. The convenient setting provides residents of Santa Clarita and surrounding communities the option to participate in clinical trials close to home.

BOSTON — (BUSINESS WIRE) - BOSTON — A research study is now available in Warwick, R.I., to evaluate the effect of an investigational treatment focused on preventing heart attack and stroke in adults with high risk, but no prior history, of major adverse cardiovascular events.

Major atherosclerotic cardiovascular disease (ASCVD) events, such as heart attack and ischemic stroke, are among the leading causes of death in the United States and worldwide. The VICTORION-1 PREVENT phase 3 study by Novartis (randomized, double-blind, placebo-controlled), may offer a way to help prevent life-threatening medical emergencies caused by the buildup of plaque in the arteries.

"The impact of heart attack and stroke can impede members of our Warwick community from living longer, healthier lives," said Dr. Sudhir Bansal, Principal Investigator for Care Access - Warwick. “This research study will enroll patients who are at increased risk, but have no prior history, of major ASCVD events. This is an exciting opportunity for our community to participate in a far-reaching study here in Warwick, rather than traveling to the city.”

The research study will enroll for adults 40 to 79 years of age who are at high risk for a first major ASCVD event, based on evidence of plaque in the coronary arteries and other factors that physicians can check for. If you or someone you know is interested or wants to participate in this study, visit managemyheartdisease.com, or contact Care Access at (351) 222-5112 to learn more.

Care Access opened its Warwick location in collaboration with Dr. Bansal and other local healthcare providers. The convenient setting provides residents of Warwick and surrounding communities the option to participate in clinical trials close to home.